Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials

• Main Authors: Lidia Oostvogels (Author), Thomas C. Heineman (Author), Robert W. Johnson (Author), Myron J. Levin (Author), Janet E. McElhaney (Author), Peter Van den Steen (Author), Toufik Zahaf (Author), Alemnew F. Dagnew (Author), Roman Chlibek (Author), Javier Diez-Domingo (Author), Iris S. Gorfinkel (Author), Caroline Hervé (Author), Shinn-Jang Hwang (Author), Hideyuki Ikematsu (Author), George Kalema (Author), Himal Lal (Author), Shelly A. McNeil (Author), Tomas Mrkvan (Author), Karlis Pauksens (Author), Jan Smetana (Author), Daisuke Watanabe (Author), Lily Yin Weckx (Author), Anthony L. Cunningham (Author)
• Format: Book
• Published: Taylor & Francis Group, 2019-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

In two pivotal efficacy studies (ZOE-50; ZOE-70), the adjuvanted recombinant zoster vaccine (RZV) demonstrated >90% efficacy against herpes zoster (HZ). Adults aged ≥50 or ≥70 years (ZOE-50 [NCT01165177]; ZOE-70 [NCT01165229]) were randomized to receive 2 doses of RZV or placebo 2 months apart. V...